BioTime Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa 2016 Annual Gathering

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that Co-CEO Dr. Michael D. West, will give a lecture at the Mensa Annual Gathering today titled, “Hayflick Rewound: Implications of Reversing the Aging of Human Cells.” Dr. West will discuss the impact of aging on society, as well as fundamental advances in understanding its causes and strategies to intervene using regenerative medicine. Dr. West will describe an online Artificial Intelligence (AI) and Deep Learning (DL) resource called “Embryonic.AI” being launched this week by LifeMap Sciences, Inc., a BioTime subsidiary, for beta testing and designed to discover novel treatments that cause the body to scarlessly repair tissue damage, an emerging field called induced Tissue Regeneration (iTR).

The venue of Mensa 2016 was chosen in order to discuss the ongoing paradigm shift relating to the use of artificially-intelligent systems to surpass human performance in areas including image recognition, autonomous driving, and biomedical research. Dr. West's presentation along with a video describing AI-based discovery and iTR will be available on BioTime's website in the Events & Presentations section under Investors & Media.

Mensa, the high IQ society, provides a forum for intellectual exchange among its members in over 100 countries around the world.

Induced Tissue Regeneration

Humans and most mammals have only a limited capacity to repair tissues in the body resulting from trauma or degenerative disease. However, some animals, such as the Mexican salamander can profoundly regenerate injured tissues, even amputated limbs. Using pluripotent stem cells and its proprietary PureStem® technology, BioTime scientists have isolated > 200 diverse embryonic progenitor cell lines with the potential to regenerate tissue in humans similar to that occurring in naturally regenerating animals. Key to the uniqueness of BioTime’s PureStem® technology is the observation that the cells produced using this proprietary method differ from adult-derived cells in that they still express molecules associated with early embryonic development when organs and tissues in the body are formed for the first time.

The transition from the ability to regenerate tissue in early embryonic development to the ability to merely produce scar tissue as adults is one of the most complex processes studied in biology today. BioTime in collaboration with Insilico Medicine is investigating the potential ability to apply machine intelligence to better understand the process. BioTime scientists believe that leading in this innovative application of AI and pluripotent stem cell technologies is key to the future of the industry. Additionally, broader applications of this system could include personalized regenerative pharmacology, cancer stem cell research, as well as advances in understanding and intervening in the aging process. This Computer-based DL program will be available online at http://discovery.lifemapsc.com and is called "Embryonic.AI." The discoveries made with Embryonic.AI have the potential to lead to the ability to induce scarless tissue regeneration in humans, an emerging field called iTR.

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world’s premier collection of pluripotent cell assets. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.

About Insilico Medicine, Inc.

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery and provides services to pharmaceutical companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

FORWARD-LOOKING STATEMENTS

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime's Securities and Exchange Commission filings. BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://news.biotimeinc.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160629005525/en/

Contact:

BioTime, Inc.
Dan L. Lawrence, 510-775-0510
dlawrence@biotimemail.com
or
Investor Contact:
EVC Group, Inc.
Michael Polyviou, 646-445-4800
mpolyviou@evcgroup.com
or
Media Contact:
Gotham Communications, LLC
Bill Douglass, 646-504-0890
bill@gothamcomm.com

Deep learning system for drug discovery to be presented at the Machine Intelligence Summit in Berlin

Artificially intelligent drug discovery engine to be presented at Machine Intelligence Summit in Berlin

Following the publication of the first proof of concept of predicting the functional properties of drugs by their transcriptional response signature, scientists at Insilico Medicine developed a multimodal input drug discovery engine capable of predicting therapeutic use, toxicity and adverse effects of thousands of molecules. Several of these advances will be presented at the Re-Work Machine Intelligence Summit Berlin, June 29-30.

Drug discovery processes within the pharmaceutical and even biotechnology companies is generally very slow, takes decades and usually results in failures with less than 1 in 10 drugs in clinical trials reaching the market. There are many reasons for high failure rates: irreproducible experiments published in top peer-reviewed journals, poor choice of animal models or inability to translate the results from animal models directly to humans, high heterogeneity of diseases and heterogeneity of the patient population and asymmetry of information among scientists, managers, venture capitalists, pharmaceutical companies and regulators. Another reason is the slow-paced and bureaucratic culture within the pharmaceutical companies. Insilico Medicine aims to address all of these reasons by developing multimodal deep learned and parametric biomarkers as well as multiple drug scoring pipelines for drug discovery and drug repurposing, hypothesis and lead generation. Many leading company scientists are hired through exhaustive hackathons and competitions. One of these scientists is Polina Mamoshina, senior research scientist at the Pharmaceutical Artificial Intelligence division of Insilico Medicine. 

"At Insilico, we want to radically transform the pharmaceutical industry and double the number of drugs on the market using artificial intelligence and deep understanding of the pharmaceutical R&D processes. We decided to start with nutraceuticals and cosmetics, but soon we will be announcing our cancer immunology concomitant drug discovery engine, to boost the response rates to checkpoint inhibitors in immuno-oncology", said Polina Mamoshina, senior research scientist at Insilico Medicine, Inc. 

Earlier this month Insilico Medicine signed an exclusive agreement with Life Extension, a major nutraceutical product vendor to collaboratively develop set of geroprotectors, natural products that mimic the healthy young state in multiple old tissues. This products are able to increase rejuvenation rate of human body and slow down or even reverse aging process.

Polina Mamoshina was the lead author on paper, "Applications of Deep Learning in Biomedicine" in Molecular Pharmaceutics and contributed to another publication, "Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data" also in Molecular Pharmaceutics. The later paper received the Editors' Choice Award from the American Chemical Society. She also co-authored a paper, "Deep biomarkers of human aging: Application of deep neural networks to biomarker development" in Aging, one of the highest-impact journals in aging research. 

"Using our drug discovery engine we made thousands of hypotheses and narrowed these down to 800 strong molecule-disease predictions with efficacy, toxicity, adverse effects, bioavailability and many other parameters. We added many drug scoring mechanisms that further validate the initial predictions and put together a team of analysts to research and evaluate individual molecules. We are now partnering with various institutions to validate these predictions in vitro and in vivo", said Alex Aliper, president of Insilico Medicine, Inc. 

Insilico Medicine previously presented the deep learned biomarkers of aging at the Re-Work Deep Learning in Healthcare conference in London before the publication of the research paper. 

"We really like Re-Work conferences as they bring together machine intelligence experts from many industries and focus on applications and benefits of various approaches. Previously we managed to meet both research and industry partners. At Insilico, we are trying to encourage women in science, especially young female scientists. This makes events run by all-female Re-Work team special for us. I highly recommend anyone interested in practical applications of AI to attend their events. ", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. 

Machine Intelligence Summit Berlin conference will transpire 29 - 30 of June 2016 at a unique church turned conference venue that is more than 100 years old located at Umweltforum, Pufendorfstr. 11, 10249 Berlin. https://www.re-work.co/events/machine-intelligence-berlin-2016

About Insilico Medicine

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AI division the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

About Re-Work

RE* WORK is an all-female run events organising company that brings together breakthrough technology, cutting-edge science and entrepreneurship shaping the future of business and society. At each event, it showcases the opportunities of exponentially accelerating technologies to positively disrupt industry and society. Leading technologists, entrepreneurs, innovators, and industry leaders on such events come together to share case studies, research and technological innovations to integrate cutting-edge technology and science into human lives. For media enquiries, interviews and images, please email: Sophie Curtis scurtis@re-work.co or call +44 203 287 0590

Life Extension™ joins with Insilico Medicine to develop advanced anti-aging technologies utilizing artificial intelligenceВ

 Life Extension™ and Insilico Medicine have announced an exclusive collaborative effort to identify novel biomarkers of human aging through the use of big data analytics and artificial intelligence, with the ultimate goal of nutrient formulation discovery to support health and longevity.

Insilico Medicine, Inc, is a big data analytics company located at the Emerging Technology Centers at the Johns Hopkins UniversityEastern campus in Baltimore, MD, specializing in applying advances in deep learning to biomarker and drug discovery. Life Extension, a Florida-based organization established in the early 1980s is dedicated to extending healthy human longevity. 

Insilico Medicine will focus on applying advanced signaling pathway activation analysis techniques and deep learning algorithms to find nutraceuticals that mimic the tissue-specific transcriptional response of many known interventions and pathways associated with health and longevity. They will also search for dietary ingredients referred to as "geroprotectors" that mimic the young healthy signaling state in older human tissues. Life Extension will use this information to develop novel nutraceutical products to support health and longevity.

"For many years I was buying a range of supplements from Life Extension, and saw how passionate they are about extending healthy human life and supporting cutting-edge research in the field," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. and the chief science officer of the Biogerontology Research Foundation in the UK. 

"Life Extension's discovery research and product development teams have decades of experience in the pharmaceutical and nutraceutical research and have set very high standards for science based nutraceutical discovery. I am excited to have the opportunity to collaborate with Life Extension to expand our research activities substantially and translate our knowledge to healthy 

Life Extension™ and Insilico Medicine have announced an exclusive collaborative effort to identify novel biomarkers of human aging through the use of big data analytics and artificial intelligence, with the ultimate goal of nutrient formulation discovery to support health and longevity.

Insilico Medicine, Inc, is a big data analytics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, MD, specializing in applying advances in deep learning to biomarker and drug discovery. Life Extension, a Florida-based organization established in the early 1980s is dedicated to extending healthy human longevity.

Insilico Medicine will focus on applying advanced signaling pathway activation analysis techniques and deep learning algorithms to find nutraceuticals that mimic the tissue-specific transcriptional response of many known interventions and pathways associated with health and longevity. They will also search for dietary ingredients referred to as "geroprotectors" that mimic the young healthy signaling state in older human tissues. Life Extension will use this information to develop novel nutraceutical products to support health and longevity.

"For many years I was buying a range of supplements from Life Extension, and saw how passionate they are about extending healthy human life and supporting cutting-edge research in the field," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. and the chief science officer of the Biogerontology Research Foundation in the UK.

"Life Extension's discovery research and product development teams have decades of experience in the pharmaceutical and nutraceutical research and have set very high standards for science based nutraceutical discovery. I am excited to have the opportunity to collaborate with Life Extension to expand our research activities substantially and translate our knowledge to healthy beneficial products," added Zhavoronkov.

Recently, Insilico Medicine published several key papers on applying deep learning techniques to biomedical applications in influential peer-reviewed journals including,

"Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data" in Molecular Pharmaceutics, a journal published by the American Chemical Society,

"Deep biomarkers of human aging: Application of deep neural networks to biomarker development" in Aging, one of the highest-impact journals in aging research,

"Applications of Deep Learning in Biomedicine", also in Molecular Pharmaceutics.

Scientists at Insilico Medicine regularly publish papers on multiple aspects of aging and longevity and geroprotector discovery. A recent publication included "Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic" in Aging Cell, another influential journal in the field.

"We believe accelerating the rate of progress in novel biomarker identification, as well as precision nutrient formulation development is critical," said Andrew G. Swick, Ph.D., senior vice president of scientific affairs, discovery research and product development for Life Extension. 

"We are excited about our collaboration with Insilico Medicine because of their outstanding academic publication record, proven ability in deep learning, and team of scientists dedicated to extending productive human longevity. Our staff looks forward to collaborating with Insilico Medicine scientists to utilize their cutting edge technology to stay at the forefront of aging and natural medicine research," says Swick.

About Life Extension 

A trailblazer in the $35 billion U.S. dietary supplement industry for the past 36 years, Life Extension's core mission is to extend the healthy human life span using an integrative approach by reporting on and funding cutting-edge scientific research. Life Extension Foundation Buyer's Club, Inc. ("Life Extension") offers a full-range of premium-quality vitamins, minerals, and hormones as well as unique, specially made formulas. The company's products are developed based on the latest scientific studies from peer-reviewed medical journals and are continually updated as new information occurs. To learn more about Life Extension, visit http://www.lifeextension.com/

About Insilico Medicine

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins UniversityEastern campus in Baltimore with R&D resources in Belgium, Russia and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AI division the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8 

New method seeks to diminish risk, maximize investment in cancer 'megafunds'

Recognizing the high research and development costs for drugs to combat cancer, a team of researchers has devised a method to maximize investment into these undertakings by spotting which efforts are the most scientifically viable. 

The work centers on "cancer megafunds," or Special Purpose Vehicles (SPVs), in which a collection of investors back a range of research projects, all designed to develop pharmaceuticals to battle cancer. By pooling resources and sponsoring multiple ventures, financial supporters aim to share the high costs of drug development, which include research and clinical trials that can run more than a decade.

However, SPVs mask risks to investors. Among these, as with many "portfolios," are "toxic assets" or "lemons" that threaten the fund by directing resources toward scientifically unsound initiatives. 

The challenge, then, is to spot these lemons before too much money has been spent on them -- or too little directed toward more worthwhile studies. In other words, what's the optimal financial strategy to increase the likelihood that an investment is paying off scientifically?

This was the aim of the method, reported in the journal Oncotarget and developed by New York University's Bud Mishra, along with his colleagues and students: Xianjin Yang of Saudi Arabia's King Abdullah University of Science and Technology, Edouard Debonneuil of the University of Lyon, and Alex Zhavoronkov, CEO of InSilico Medicine. 

The paper may be downloaded here: http://bit.ly/1PAjYyh.

The team analyzed their proposed financial model by mathematical analysis, followed by a series of simulations designed to replicate early-stage investment, which is the most risky portion of this process and when funding is scarce. It used one semester (approximately 15 weeks) as a unit of time and six years as the duration of the drug-development enterprise.

The team's calculations revealed that many SPVs simply contain too many projects, many of which are bound to be "lemons"--i.e., have zero chance of resulting in an effective drug to fight cancer. Therefore, maximizing the value of these megafunds means not only eliminating a large percentage of projects from a portfolio early on in the process, but also assessing which are likely to be viable and which are not. 

Their simulations pointed to some principles for a sound investment strategy. Among these is determining an optimal percentage of upfront costs to direct toward validating the scientific promise of a particular drug -- for example, 25 percent. In addition, their approach also includes making all investors aware of which projects have promise and which are "lemons" -- so as to prevent any one investor from taking advantage of information not available to others.

"Ultimately, such an unfortunate outcome could lead the financial markets to completely lose their appetite for megafunds," observes Mishra. "The principles studied here could be helpful: they will strongly improve the yields and risks associated with securitization, but also limit the possibility of hiding defects of the 'lemon' projects."

"The principles introduced in this paper go beyond cancer megafunds and may be applied more broadly, helping finance biomedical research to address a wide range of diseases, including rare diseases, as well as extend into aging and longevity and providing pension funds with new instruments to hedge longevity risk," notes Zhavoronkov.

So, in short, the approach centers on: validation of drug development programs and transparency about the main results of validation. Their simulations indicate that without such a principled approach, the result would be financially disastrous megafunds -- but presented as attractive.

Advances in deep learning to be presented at ISFA-Columbia University workshop in Lyon

ISFA-Columbia University workshop to cover advances in deep learning in biomedicine.

Insilico Medicine scientists to present the advances in deep learning in biomedicine at the ISFA-Columbia University Actuarial Science Workshop on June 27th and 28th in Lyon, France. Actuarial science is one of the disciplines, which deals with population-level big data to assess risk in finance, insurance, pensions and many other industries. In recent years advances in deep learning fuelled by the availability of big data and high-performance GPU computing enabled algorithms achieve superhuman accuracy in many tasks including image, voice and text recognition, autonomous driving, playing video games and complex games like Go. However, these advances have not yet propagated into mainstream use by the actuaries and ISFA-Columbia University Workshop may set the stage for Deep Actuarial Science. 

"Actuaries are perhaps among the least famous scientists and do not frequently make headlines, but these scientists are making the world's economy tick. Actuaries are in charge of building mortality tables, where one decimal point may result in trillions of dollars in liabilities and sophisticated risk models with global impact. We are very happy to present at ISFA events because the organizers are not only top experts in the field, but also have a vision for bringing new technologies and concepts into both the actuarial and longevity science", said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. 

INSTITUT DE SCIENCE FINANCIERE ET D'ASSURANCES (ISFA) established in 1930 and headquartered in Lyon, France is one of the oldest and most respected actuarial institutes in the world training thousands of actuaries and performing cutting-edge research at the LABORATOIRE DE SCIENCES ACTUARIELLE & FINANCIERE (SAF). It frequently organizes international conferences and meetings bringing together actuaries from all over the world. In 2015, it hosted Longevity'11 actuarial conference with the Cass Business School.

Insilico Medicine recently published two papers demonstrating deep biomarkers of human aging and providing an overview of deep learning applications in biomedicine and expects more papers demonstrating applications of DL to drug discovery and biomarker development to be published shortly. 

"While being very strict and conservative, actuarial science is a constantly evolving field and at ISFA we are constantly innovating introducing new technologies and computational methods, as well as fostering out of the box thinking. Deep learning demonstrated spectacular results in many areas and we invited scientists from Insilico Medicine to present their results in biomarker development and drug discovery and to discuss recent trends", said Dr. Stephane Loisel, professor at ISFA and co-organizer of the ISFA-Columbia workshop. 

The registration deadline for the event is June 15th and actuaries, insurance and pension funds managers and other financial professionals are encouraged to register and attend the event. 

"We are entering a new era in actuarial science, when advances big data analytics and artificial intelligence in concert with better understanding of many biological processes will transform the way we look at risk, build models and make predictions. This conference will be a major milestone in this new era and I encourage everyone in actuarial science and financial engineering to attend", said Edouard Debonneuil, CEO of ActuRx and researcher at ISFA. 

About Insilico Medicine 

Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore with R&D resources in Belgium, Russia and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AIdivision the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8

ABOUT INSTITUT DE SCIENCE FINANCIERE ET D'ASSURANCES (ISFA) 

The Institute for Financial Science and Insurance was founded in Lyon-France in 1930. This is one of the oldest institutes providing a large output of actuaries with the major financial and insurance companies.

Graduate school of University Claude Bernard Lyon 1, ISFA is one of the best actuarial education institutions in Europe. I.S.F.A. actuarial degree is fully accredited by the Institut des Actuaires, member of International Actuarial Association - IAA. Website: http://isfa.univ-lyon1.fr

ETC Baltimore Company Makes Major Advances in Artificial Intellegence for Drug Discovery

Artificial intelligence may streamline pharmaceutical R&D by predicting pharmacological properties of small molecules in silico

The ETC (Emerging Technology Centers) today announced major advances in deep learning for pharmaceutical R&D made by one of their member companies located at its ETC Eastern Campus since February 2014. In the course of one week, the company announced the publication of two papers demonstrating proof of concept of applications of deep neural networks to drug discovery and repurposing in “Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data” in Molecular Pharmaceutics, one of the influential American Chemical Society journals, and biomarker development in “Deep biomarkers of human aging: Application of deep neural networks to biomarker development” in Aging, one of the highest-impact journals in aging research. 

“We are very happy to host innovative companies developing artificial intelligence (AI) solutions for practical applications in healthcare. I hope that AI solutions developed by Insilico Medicine, will help accelerate drug discovery and reduce the number of failures in clinical trials”, said Deb Tillett, President of the ETC. 

Over the past half century, pharmaceutical research and development process slowed down, while costs associated with bringing drugs to market increased due to high failure rates in clinical trials, regulatory issues and changing industry structure. New approaches are needed to accelerate discovery of novel compounds, evaluate their efficacy and safety and reduce failure rates. At every step of the pharmaceutical drug development process artificial intelligence holds a lot of promises. Advances in deep learning enabled artificially-intelligent systems surpass humans in image, voice and text recognition, autonomous driving and other tasks. But scarcity and variability of biomedical data and shortage of professionals with domain expertise in both deep learning and drug and biomarker discovery are impeding the propagation of AI into the pharmaceutical industry. Companies like Insilico Medicine are pioneering the field by developing and publishing practical applications of deep learning providing valuable insights into the future of the industry.

“ETC is a perfect place to start building a high-tech business in Baltimore. Being located at one of the campuses of one of the world’s greatest medical universities, access to premium facilities, services and experts in a variety of fields, 24-hour operation and high-speed Internet access make it a perfect control center for our global operations aiming at transforming the way we discover drugs and monitor their efficacy”, said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc. 

“Over the past 12 months our scientists published 21 research papers in peer-reviewed journals primarily focusing on bioinformatics of cancer and aging, but we are most proud of our two papers on deep learning published last week. And these papers are just the tip of the iceberg of what we have internally and what is being developed. Advances in deep learning changed our company from a service provider catering to pharmaceutical companies into a drug discovery company with almost a thousand compounds with efficacy, toxicity and other predicted parameters and soon we will be announcing our first partnership deals”, said Qingsong Zhu, PhD, COO of Insilico Medicine, Inc.

In addition to the articles being published in Molecular Pharmaceutics and Aging, Insilico’s “Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data” was selected as Editor’s Choice in the American Chemical Society Publication.

About Insilico Medicine
Insilico Medicine, Inc. is a bioinformatics company located at the Emerging Technology Centers Campus located at the Johns Hopkins University at Eastern in Baltimore with R&D resources in Belgium, Russia and Poland hiring talent through hackathons and competitions. It utilizes advances in genomics, big data analysis and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. The company pursues internal drug discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and geroprotector discovery. Through its Pharma.AI division the company provides advanced machine learning services to biotechnology, pharmaceutical and skin care companies. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8 

About ETC (Emerging Technology Centers)
The ETC, a venture of the Baltimore Development Corporation, is a 501(c) (3) technology and innovation center focused on growing early-stage companies. The ETC provides three programs for entrepreneurs: a tech focused incubator, Incubate Baltimore, a seed accelerator program, Accelerate Baltimore and a coworking space open to innovative individuals and teams, Beehive Baltimore. The ETC promotes economic development, providing business, technical, and networking connections to help these companies grow. Since 1999, the ETC has provided assistance to over 350 companies, 85% of which are still in business, creating more than 2,500 jobs and raising more than $2.2 Billion in outside funding.